Safety Assessment of Zigbir®: A Polyherbal Formulation in Sprague-Dawley Rats

Table 2

Haematological findings (mean ± SD) in male rats after 90 days subchronic oral administration of Zigbir®.

Parameters	Control	250 mg/kg	500 mg/kg	1000 mg/kg	Control recovery	1000 mg/kg recovery
Hb (g%)	15.15 ± 1.45	15.39 ± 0.60	15.07 ± 0.59	14.89 ± 0.99	16.34 ± 1.60	16.50 ± 0.83
Total RBC (×10^6/𝜇L)	7.00 ± 0.82	8.52** ± 0.60	7.50 ± 0.53	7.51 ± 0.50	8.35 ± 0.93	8.65 ± 0.34
Rt (%)	1.66 ± 0.42	1.59 ± 0.36	1.53 ± 0.41	1.60 ± 0.41	1.58 ± 0.41	1.66 ± 0.40
HCT (%)	38.38 ± 3.39	42.52** ± 1.77	40.65 ± 1.39	39.62 ± 2.47	45.58 ± 3.73	46.06 ± 2.30
MCV (𝜇m^3)	55.01 ± 2.26	50.04** ± 2.23	54.33 ± 3.21	52.77 ±1.51	54.70 ± 2.40	53.26 ± 1.80
MCH (pg)	21.71 ± 0.98	18.09** ± 0.98	20.20** ± 1.29	19.81** ± 0.62	19.58 ±1.08	19.10 ± 0.75
MCHC (%)	39.48 ± 0.71	36.17** ± 0.54	37.15** ± 0.83	37.54** ± 0.36	35.80 ± 0.81	35.82 ± 0.33
Platelets (×10^3/𝜇L)	396.90 ± 38.04	399.70 ± 67.67	394.40 ± 69.40	404.10 ± 84.93	453.00 ± 32.61	443.40 ± 66.39
Total WBC (×10^3/𝜇L)	11.09 ± 2.94	12.52 ± 3.63	15.41* ± 4.79	13.53 ± 1.72	8.76 ± 2.06	10.84 ± 1.81
N (%)	21.60 ± 4.22	21.10 ± 2.92	20.90 ± 3.48	20.80 ± 4.49	20.40 ± 3.21	21.20 ± 3.11
L (%)	75.20 ± 3.99	75.90 ± 2.60	75.60 ± 3.57	76.20 ± 4.44	76.20 ± 2.95	75.80 ± 3.11
E (%)	1.50 ± 0.85	1.20 ± 0.79	1.10 ± 0.88	1.30 ± 0.82	1.20 ± 0.84	1.20 ± 0.84
M (%)	1.70 ± 0.95	1.80 ± 0.79	2.40 ± 0.84	1.70 ± 1.25	2.20 ± 0.84	1.80 ± 1.48
B (%)	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Pt (s)	14.80 ± 2.44	14.60 ± 2.27	15.10 ± 2.77	15.30 ± 2.54	15.20 ± 2.39	15.60 ± 3.13

∗P < 0.05 versus control group.
∗∗P < 0.01 versus control group.